PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
13/10/2021 24:59
Australia Stock Exchange release from PHARMAXIS LTD PXS.AX : PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
- AU$37.28m
- AU$23.71m
- AU$6.84m
Australia Stock Exchange release from PHARMAXIS LTD PXS.AX : PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial